Document Detail

Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism?
MedLine Citation:
PMID:  17333160     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Although the treatment of schizophrenia with many second generation antipsychotics is known to be associated with metabolic changes, such as hyperglycemia or hypercholesterolemia, the underlying mechanisms of these adverse reactions remain unclear. In light of the recent focus on the involvement of semicarbazide-sensitive amine oxidase (SSAO) in glucose metabolism, we investigated SSAO serum activity in schizophrenic patients treated with antipsychotics with the objective of determining a possible link between SSAO and impaired glucose metabolism. METHODS: Blood samples were drawn from 44 schizophrenic patients (24 receiving second generation antipsychotics known to disturb glucose metabolism) on day 1 and day 5 of inpatient treatment. Forty-one healthy adults with no medical condition known to influence SSAO served as controls. RESULTS: Of the 44 schizophrenic patients, the 24 treated with second generation antipsychotics known to disturb glucose metabolism showed significantly lower SSAO serum activity [day 1 (mean +/- SD): 477 +/- 105 mU/L; day 5: 438 +/- 86 mU/L] than the 20 patients treated with other antipsychotics not known to influence glucose metabolism (day 1: 513 +/- 124 mU/L, p = 0.359; day 5: 542 +/- 204 mU/L, p = 0.021) only after 5 days of treatment and compared to healthy controls (526 +/- 142 mU/L, p = 0.021). No differences were observed between schizophrenic patients treated with first generation antipsychotics and the controls. CONCLUSION: We found decreased SSAO serum activity exclusively in schizophrenic patients treated with second generation antipsychotics known to disturb glucose metabolism. In terms of the role of SSAO in glucose metabolism, the observed decrease in SSAO serum activity may be linked to metabolic changes that are known to occur in schizophrenic patients being treated with many second generation antipsychotics.
Veit Roessner; Annette Weber; Andreas Becker; Georg Beck; Helge Frieling; Stefan Bleich
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2007-02-28
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  63     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-03     Completed Date:  2007-08-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  425-9     Citation Subset:  IM    
Department of Psychiatry and Psychotherapy, University of Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amine Oxidase (Copper-Containing) / blood,  drug effects*,  metabolism
Antipsychotic Agents / adverse effects*,  pharmacology,  therapeutic use
Glucose / metabolism*
Middle Aged
Multivariate Analysis
Pilot Projects
Schizophrenia / drug therapy*
Reg. No./Substance:
0/Antipsychotic Agents; 50-99-7/Glucose; EC Oxidase (Copper-Containing)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
Next Document:  Idiopathic inflammatory-demyelinating diseases of the central nervous system.